Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products. The Generics segment develops and sells approximately 100 oral and other non-injectable generic products for oncology and pain management, as well as respiratory, nasal spray, suspension, liquid solution, and high-containment areas. The Branded segment develops, manufactures, and markets branded generics and in-licensed products, such as anti-infective products, as well as chronic therapeutic categories comprising cardiovascular, diabetes, CNS, and oncology products. The company also manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+44-20-73992760
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees8,400
Next Earnings DateN/A
OptionableNot Optionable
Hikma Pharmaceuticals (OTCMKTS:HKMPY) Frequently Asked Questions
What is Hikma Pharmaceuticals' stock symbol?
Hikma Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HKMPY."
What is the consensus analysts' recommendation for Hikma Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hikma Pharmaceuticals.
Has Hikma Pharmaceuticals been receiving favorable news coverage?
News stories about HKMPY stock have trended somewhat positive on Thursday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Hikma Pharmaceuticals earned a news impact score of 1.7 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Hikma Pharmaceuticals.
Who are some of Hikma Pharmaceuticals' key competitors?
Some companies that are related to Hikma Pharmaceuticals include 1933 Industries (TGIF), Abacus Health Products (ABAHF), Acreage (ACRGF), Alliance Growers (ACG), Applied Biosciences (APPB), Ayr Strategies (AYRSF), Biome Grow (BIO), Blueberries Medical (BBM), Canbiola (CANB), Cannabis Science (CBIS), Cannara Biotech (LOVE), Cansortium (CNTMF), cbdMD (YCBD), Charlotte's Web (CWBHF) and Choom (CHOOF).
What other stocks do shareholders of Hikma Pharmaceuticals own?
Who are Hikma Pharmaceuticals' key executives?
Hikma Pharmaceuticals' management team includes the folowing people:
- Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 62)
- Mr. Mazen Samih Taleb Darwazeh, Exec. Vice Chairman, CEO and Pres of MENA & Emerging Markets (Age 61)
- Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 50)
- Mr. Khalid Walid Hussni Nabilsi, Chief Financial Officer (Age 47)
- Dr. Surendera Tyagi, Group Chief Scientific Officer and Global Head of R&D
How do I buy shares of Hikma Pharmaceuticals?
Shares of HKMPY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Hikma Pharmaceuticals' stock price today?
One share of HKMPY stock can currently be purchased for approximately $51.36.
What is Hikma Pharmaceuticals' official website?
How can I contact Hikma Pharmaceuticals?
Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760.
MarketBeat Community Rating for Hikma Pharmaceuticals (OTCMKTS HKMPY)
MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals and other stocks. Vote "Outperform" if you believe HKMPY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HKMPY will underperform the S&P 500 over the long term. You may vote once every thirty days.
